TL;DR
- •Atypical antidepressants don't fit neatly into SSRI/SNRI categories — each works through a different receptor profile.
- •Wellbutrin (NDRI) targets dopamine + norepinephrine; useful when SSRI-related sexual dysfunction or emotional blunting is a problem.
- •Trintellix has multimodal serotonin activity plus a unique cognitive benefit — often used when patients want depression treatment that doesn't blunt focus.
- •Auvelity (dextromethorphan + bupropion) is FDA-approved for fast-acting depression treatment — measurable response in days rather than weeks, working partly through NMDA antagonism.
- •Remeron (mirtazapine) increases both serotonin and norepinephrine through a different mechanism; often used when sleep + appetite need improvement alongside mood.
- •Trazodone is most commonly used off-label for insomnia at low doses; full antidepressant doses are sedating and less commonly used.
How this class works
This class covers everything that isn't a straightforward SSRI, SNRI, MAOI, or tricyclic. Each medication has its own receptor profile. The clinical use case for atypicals is usually "the patient needs an antidepressant but the side-effect profile of SSRIs/SNRIs doesn't fit." For example: Wellbutrin doesn't cause sexual dysfunction; Trintellix has cognitive benefits; Auvelity acts within days through NMDA antagonism (similar mechanism family as ketamine).
Medications in this class
Tovani has detailed drug-interaction pages for 4 atypical antidepressants. Click any to see the ketamine-interaction verdict, mechanism, and FAQ.
Why patients look for alternatives
- •SSRI-related sexual dysfunction that won't resolve
- •Need fast-acting treatment (consider Auvelity over SSRIs)
- •Cognitive symptoms (brain fog, attention) that SSRIs don't help
- •Sleep disruption from existing antidepressant
- •Comorbid smoking — Wellbutrin doubles as smoking-cessation aid
- •Multiple SSRI/SNRI failures and considering different mechanism
Where ketamine fits
Clinical indication
For depression that has resisted multiple atypical trials, ketamine's NMDA/glutamate mechanism is fundamentally different from any of these (with the partial exception of Auvelity, which uses dextromethorphan's mild NMDA antagonism). Ketamine produces full NMDA antagonism with measurable effect within hours.
Onset comparison
Hours for ketamine vs days for Auvelity vs 4-8 weeks for most other atypicals. If onset speed is your main concern, ketamine and Auvelity are the two fast-acting options — they overlap mechanistically.
Contraindications and coordination
If you're on Auvelity (dextromethorphan + bupropion), be especially explicit during consultation — the dextromethorphan component has overlap with ketamine's NMDA mechanism. Other atypicals generally combine safely. Active substance use disorder, uncontrolled cardiovascular disease, and active psychotic disorder are general contraindications.
5-minute screening · Reviewed by a board-certified physician · FL & NJ
Other alternatives worth knowing about
Ketamine isn’t the only escalation path. These are the other options your physician may consider, depending on your history.
Cycling through other atypicals
Switching between atypicals (Wellbutrin → Trintellix → Auvelity → Remeron) is common when each has produced partial response. Each receptor profile is different enough to give meaningful additional information.
Augmentation with mood stabilizers or antipsychotics
Lithium, Lamictal, Abilify, or Seroquel added to an existing antidepressant. Particularly common with Wellbutrin since it doesn't affect serotonin much.
TMS for treatment-resistant depression
Non-pharmacological in-clinic option, ~30 sessions over 6 weeks. Strong evidence in patients who've failed multiple antidepressant classes.
Therapy plus medication combination
CBT or other evidence-based psychotherapy combined with whatever medication is currently working partially. Combination typically outperforms either alone.
Frequently asked
What's the difference between Wellbutrin and SSRIs?
Wellbutrin (bupropion) works on dopamine and norepinephrine reuptake — not serotonin. Clinical implications: no sexual dysfunction (a common SSRI complaint), no weight gain (often weight loss), some attention benefit, but also somewhat lower seizure threshold (avoid in patients with seizure history) and not first-line for anxiety. For SSRI side-effect intolerance, Wellbutrin is the most common alternative.
Is Auvelity really faster than other antidepressants?
Yes — Auvelity's dextromethorphan component provides mild NMDA antagonism (mechanistic cousin to ketamine), producing measurable response in days rather than the 4-8 weeks for traditional antidepressants. It's FDA-approved for major depression on this basis. The trade-off: it's newer and more expensive than generic alternatives. For patients who need fast onset, it's a reasonable choice; for cost-sensitive long-term use, traditional antidepressants may make sense.
Can I take Wellbutrin alongside my SSRI?
Yes — combining an SSRI with Wellbutrin is a well-established augmentation strategy. The complementary receptor profiles (serotonin + dopamine/norepinephrine) often produce better outcomes than either alone. The combination also tends to mitigate SSRI-related sexual dysfunction and weight gain. Your physician will manage dosing to minimize seizure risk and other interactions.
If Auvelity already has NMDA antagonism, do I need ketamine too?
Auvelity's NMDA effect is mild — significantly weaker than ketamine's. Patients on Auvelity who haven't had adequate response are sometimes referred for ketamine, which provides the same mechanism at therapeutic intensity. If you're currently on Auvelity and considering ketamine, that's a clinical conversation about whether the partial NMDA effect is or isn't producing the response you need.
Will ketamine combine with these medications?
In most cases yes. Most atypicals work through different mechanisms than NMDA/glutamate. The exception worth flagging is Auvelity — its dextromethorphan overlaps with ketamine's NMDA effect, so coordination with your prescribing physician is essential to avoid duplicate mechanism risk. Your Tovani consultation will review your full medication list and address any specific concerns.
References
- Cipriani A et al. 2018, Lancet. Network meta-analysis ranked atypical antidepressants alongside SSRIs/SNRIs in the top efficacy tier for major depression — supporting their use as alternatives within the same effectiveness range. PMID 29477251
- Sanacora G et al. 2017, JAMA Psychiatry. APA consensus on ketamine's role for treatment-resistant depression including patients who have failed multiple atypical antidepressant trials. PMID 28249076